Clinical Trial Update: Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for TNhYP218 anti-mesothelin CAR T cells in mesothelin-expressing solid tumors, including mesothelioma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Lung Cancer
• Mesothelioma
• Ovarian Cancer
• Pancreatic Cancer
• Stomach Cancer
• Thymic Cancer

Drugs mentioned

• TNhYP218 CAR T cells (TNhYP218 CAR T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma, Neoplasms | Phase 1 | Status: RECRUITING